A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Investegate | Company News | Corporate, London Stock Exchange, Regulatory News Headlines Sensyne signs government deal for covid tests study investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Oxford, U.K. 5 February 2021 : Sensyne Health plc (LSE: SENS) ( Sensyne or the Company or the Group ), the UK Clinical AI company, announces that it has appointed Hina Zaman as Managing Director of its Healthcare Division and Martin Gouldstone as Chief Business Officer of its Life Sciences Division. Hina Zaman joins Sensyne from Babylon Health, where as Product Director she led the company s global product for value-based care and previously its global product proposition in the women s health space. Prior to that, Hina founded the UK s first virtual care platform for women s health, pioneering a new model of personalised, proactive care for health consumers. Hina has extensive experience as a healthcare management consultant, leading change initiatives across the NHS commissioning and provider landscape while at Finnamore Ltd. (now part of GE Healthcare), and in US healthcare systems while at Deloitte
Oxford, UK; 21 January 2021: Sensyne Health plc (LSE: SENS) ( Sensyne or the Company or the Group ), the UK Clinical AI company, today announces its Interim Results for the six months ended 31 October 2020. I am pleased to report that Sensyne has made significant commercial progress over the past six months and has achieved several key milestones in the development of its research partnerships with NHS Trusts and in its work for leading pharmaceutical companies applying Clinical AI to improve patient care and accelerate life sciences research. I am particularly pleased with the results we have been able to achieve during the COVID-19 pandemic.